Charles River to Produce GMP Plasmid DNA for AAVantgarde

Will develop the plasmid DNA for AAVantgarde’s Stargardt’s disease program (AAVB-039), using its AAV-intein platform.

Author Image

By: Charlie Sternberg

Associate Editor

Charles River Laboratories International Inc. and AAVantgarde have entered a contract development and manufacturing organization (CDMO) agreement to produce Good Manufacturing Practice- (GMP) plasmid DNA. AAVantgarde, a clinical-stage biotechnology company, will leverage Charles River’s expertise in manufacturing GMP plasmid DNA. AAVantgarde has two proprietary AAV-based large gene delivery platforms, both of which aim to enable efficient delivery of large genes to tissue and cells in vi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters